A high-content cell-based CNS drug screening platform - Label-free multiparametric monitoring & early detection of CNS dysfunctions in in vitro neurodegenerative disease models.

• Unité de recherche: INNOSUISSE
• Numéro de projet: 10206.2;5 PFLS-LS
• Titre du projet anglais: A high-content cell-based CNS drug screening platform - Label-free multiparametric monitoring & early detection of CNS dysfunctions in in vitro neurodegenerative disease models.

Description succincte (Anglais)

A high-content cell-based CNS drug screening platform - Label-free multiparametric monitoring & early detection of CNS dysfunctions in in vitro neurodegenerative disease models.

Description succincte (Français)

A high-content cell-based CNS drug screening platform - Label-free multiparametric monitoring & early detection of CNS dysfunctions in in vitro neurodegenerative disease models.

Résumé des résultats (Abstract) (Anglais)

This project will develop drug screening platforms for diseases of the nervous system based on the MEA technology platform. Its objectives are: a) development of multi-electrode arrays with design improvements that increase throughput and allow the measurement of specialized endpoints; a) creation of new in vitro disease models that represent a broader scope of human neurologic disorders; b) conception of new analysis strategies and software to facilitate the determination of specific molecular and cellular targets of disease-related changes in neuronal or neuromuscular activity; incorporation of the above biological models and strategies

Résumé des résultats (Abstract) (Français)

This project will develop drug screening platforms for diseases of the nervous system based on the MEA technology platform. Its objectives are: a) development of multi-electrode arrays with design improvements that increase throughput and allow the measurement of specialized endpoints; a) creation of new in vitro disease models that represent a broader scope of human neurologic disorders; b) conception of new analysis strategies and software to facilitate the determination of specific molecular and cellular targets of disease-related changes in neuronal or neuromuscular activity; incorporation of the above biological models and strategies